Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1436]

Summary of breaking prostate news from ASCO 2014

Prof Eleni Efstathiou and Prof Gordon McVie

Summary of breaking prostate news from ASCO 2014 ( Prof Eleni Efstathiou and Prof Gordon McVie )

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for...

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: Adjuvant ipilimumab in high-risk melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: Immunotherapy combo increases median survival in advanced melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Immunotherapy combo increases median survival in advanced melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Success for ipilimumab and nivolumab combo in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Success for ipilimumab and nivolumab combo in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid...

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute...

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain

Regorafenib shows early promise in colorectal candidates unable to undergo chemo ( Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain )

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck...

Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers ( Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA )

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Lapatinib not found to be beneficial in head and neck cancer with high risk of...

Prof Kevin Harrington - Institute of Cancer Research, London, UK

Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )

More from ecancer